161 related articles for article (PubMed ID: 6117153)
1. Current concepts of abnormal motor disorder: an experimental model of attentional deficit disorder.
Wray SR; Melville GN; Grell GA; Edge PC
West Indian Med J; 1981 Sep; 30(3):107-18. PubMed ID: 6117153
[No Abstract] [Full Text] [Related]
2. GABA and movement disorders.
Marsden CD; Sheehy MP
Adv Biochem Psychopharmacol; 1981; 30():225-34. PubMed ID: 6460427
[No Abstract] [Full Text] [Related]
3. The neuropharmacology of tardive dyskinesia, spontaneous dyskinesia, and other dystonias.
Stahl SM; Davis KL; Berger PA
J Clin Psychopharmacol; 1982 Oct; 2(5):321-8. PubMed ID: 6127351
[TBL] [Abstract][Full Text] [Related]
4. Neurotransmitter interactions related to central dopamine neurons.
Lloyd KG
Essays Neurochem Neuropharmacol; 1978; 3():129-207. PubMed ID: 30628
[No Abstract] [Full Text] [Related]
5. GABA in the striatonigral and striatopallidal systems as moderator and mediator of striatal functions.
Scheel-Krüger J
Adv Neurol; 1984; 40():85-90. PubMed ID: 6141713
[No Abstract] [Full Text] [Related]
6. Regulatory peptides in animal paradigms of neuropsychiatric illness.
Diamond BI; Borison RL
Adv Biochem Psychopharmacol; 1982; 33():541-8. PubMed ID: 6214928
[No Abstract] [Full Text] [Related]
7. Dysphagia in movement disorders.
Logemann JA
Adv Neurol; 1988; 49():307-16. PubMed ID: 2964174
[No Abstract] [Full Text] [Related]
8. Behavioural disorders induced by external globus pallidus dysfunction in primates: I. Behavioural study.
Grabli D; McCairn K; Hirsch EC; Agid Y; Féger J; François C; Tremblay L
Brain; 2004 Sep; 127(Pt 9):2039-54. PubMed ID: 15292053
[TBL] [Abstract][Full Text] [Related]
9. Movement disorders: why don't those synapses fire?
Zemlak V; Woldehana A
Axone; 1992 Dec; 14(2):46-9. PubMed ID: 1337267
[TBL] [Abstract][Full Text] [Related]
10. Alleviation of motor hyperactivity and neurochemical deficits by endocannabinoid uptake inhibition in a rat model of Huntington's disease.
Lastres-Becker I; Hansen HH; Berrendero F; De Miguel R; Pérez-Rosado A; Manzanares J; Ramos JA; Fernández-Ruiz J
Synapse; 2002 Apr; 44(1):23-35. PubMed ID: 11842443
[TBL] [Abstract][Full Text] [Related]
11. Progesterone attenuates neuroleptic-induced orofacial dyskinesia via the activity of its metabolite, allopregnanolone, a positive GABA(A) modulating neurosteroid.
Bishnoi M; Chopra K; Kulkarni SK
Prog Neuropsychopharmacol Biol Psychiatry; 2008 Feb; 32(2):451-61. PubMed ID: 17988775
[TBL] [Abstract][Full Text] [Related]
12. Brain neurotransmitters and neuromodulators in pediatrics.
Johnston MV; Singer HS
Pediatrics; 1982 Jul; 70(1):57-68. PubMed ID: 6123978
[TBL] [Abstract][Full Text] [Related]
13. [Tardive dyskinesia: clinical picture, prevalence, and pathophysiology].
Wöller W; Tegeler J
Fortschr Neurol Psychiatr; 1983 Apr; 51(4):131-57. PubMed ID: 6134658
[No Abstract] [Full Text] [Related]
14. Growth hormone secretion in neurological disorders.
Martinez-Campos A; Giovannini P; Cocchi D; Zanardi P; Parati EA; Caraceni T; Müller EE
Adv Biochem Psychopharmacol; 1981; 28():521-40. PubMed ID: 6452036
[No Abstract] [Full Text] [Related]
15. Tardive dyskinesia: a biological appraoch.
Barbaccia ML; Trabucchi M
Prog Clin Biol Res; 1980; 39():181-93. PubMed ID: 6105670
[No Abstract] [Full Text] [Related]
16. Antagonism of metabotropic glutamate receptor type 5 attenuates l-DOPA-induced dyskinesia and its molecular and neurochemical correlates in a rat model of Parkinson's disease.
Mela F; Marti M; Dekundy A; Danysz W; Morari M; Cenci MA
J Neurochem; 2007 Apr; 101(2):483-97. PubMed ID: 17359492
[TBL] [Abstract][Full Text] [Related]
17. [Changes in neural networks by conditional transgenic approach: a key to our comprehension of neuro-psychiatric disorders in the basal ganglia system].
Schiffmann SN
Bull Mem Acad R Med Belg; 2009; 164(7-9):171-8; discussion 178-80. PubMed ID: 20218186
[TBL] [Abstract][Full Text] [Related]
18. Movement disorders in the elderly.
Gilmore R
Geriatrics; 1984 Jun; 39(6):65-8, 72-6. PubMed ID: 6144615
[No Abstract] [Full Text] [Related]
19. Cholinergic imbalance hypotheses of psychoses and movement disorders: strategies for evaluation.
Davis KL; Hollister LE; Berger PA; Barchas JD
Psychopharmacol Commun; 1975; 1(5):533-43. PubMed ID: 132684
[TBL] [Abstract][Full Text] [Related]
20. Catecholamines and neurologic diseases (second of two parts).
Moskowitz MA; Wurtman RJ
N Engl J Med; 1975 Aug; 293(7):332-8. PubMed ID: 125386
[No Abstract] [Full Text] [Related]
[Next] [New Search]
